Bert Reichert

Bert Reichert

Auto-generated profile, based on publicly available information

Bert Reichert

Klinikum Nürnberg-Süd

Research Focus & Metrics

Academic Career Length

27Years (2000-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 December 2022 in Journal of Plastic, Reconstructive & Aesthetic Surgery
Verified
Journal Article
Closed access
David BreidungDavid Breidung
David Breidung
AMAsja T. Malsagova
Asja T. Malsagova
ABAndrè A. Barth
Andrè A. Barth
IMIoannis-Fivos Megas
Ioannis-Fivos Megas
MBMoritz Billner
Moritz Billner
BRBert Reichert
Bert Reichert

1 May 2022 in Burns
Verified
Journal Article
Closed access
DPDominik Promny
Dominik Promny
JAJuliane Aich
Juliane Aich
TPTamas Püski
Tamas Püski
AEAlejandro Marti Edo
Alejandro Marti Edo
BRBert Reichert
Bert Reichert
MBMoritz Billner
Moritz Billner

10 February 2022 in Burns
Verified
Journal Article
Closed access
Oliver ThammOliver Thamm
Oliver Thamm
RLRolf Lefering
Rolf Lefering
MBMartin Bialke
Martin Bialke
BRBert Reichert
Bert Reichert
HRHans-Oliver Rennekampff
Hans-Oliver Rennekampff
IKIngo Königs
Ingo Königs

1 May 2005 in Journal of Reconstructive Microsurgery
Verified
Journal Article
Closed access
HMHans-Günther Machens
Hans-Günther Machens
FSFrank Siemers
Frank Siemers
MKMichael Kaun
Michael Kaun
BKBjörn Krapohl
Björn Krapohl
BRBert Reichert
Bert Reichert
PMPeter Mailänder
Peter Mailänder
The authors' experience indicates that good functional results are achievable in cases with wide resection of the knee extensor mechanism. They report a low-grade myxoid fibrosarcoma patient in whom a one-stage functional reconstruction was carried out by transfer of a free latissimus dorsi flap without secondary surgical procedures.

1 January 2013 in Trials
Verified
Journal Article
Open access
PDF file
ABAugustinus Bader
Augustinus Bader
UDUlf Dornseifer
Ulf Dornseifer
SESilvia Egert
Silvia Egert
SDSebastian Dunda
Sebastian Dunda
GGGerrit Grieb
Gerrit Grieb
HMHans-Günther Machens
Hans-Günther Machens
Although it was initially assumed that erythropoietin (EPO) was a hormone that only affected erythropoiesis, it has now been proposed that EPO plays an additional key role in the regulation of acute and chronic tissue damage. Via the inhibition of inflammatory reactions and of apoptosis, stem cell recruitment, advancement of angiogenesis and growth factor release, EPO enhances healing and thus restitutio ad integrum after trauma. Human skin contains EPO receptors and is able to synthesize EPO. We therefore hypothesize that EPO is able to optimize wound healing in thermally injured patients. This is a large, prospective, randomized, double-blind, multi-center study, funded by the German Federal Ministry of Education and Research, and fully approved by the designated ethics committee. The trial, which is to investigate the effects of EPO in severely burned patients, is in its recruitment phase and is being carried out in 13 German burn care centers. A total of 150 patients are to be enrolled to receive study medication every other day for 21 days (EPO 150 IU/kg body weight or placebo). A follow-up of one year is planned. The primary endpoint of this study is the time until complete re-epithelialization of a defined skin graft donor site is reached. Furthermore, clinical parameters such as wound healing, scar formation (using the Vancouver scar scale), laboratory values, quality of life (SF-36), angiogenic effects, and gene- and protein-expression patterns are to be determined. The results will be carefully evaluated for gender differences. We are seeking new insights into the mechanisms of wound healing in thermally injured patients and more detailed information about the role EPO plays, specifically in these complex interactions. We additionally expect that the biomimetic effects of EPO will be useful in the treatment of acute thermal dermal injuries. EudraCT Number: 2006-002886-38, Protocol Number: 0506, ISRCT Number: http://controlled-trials.com/ISRCTN95777824/ISRCTN95777824.

Verified
Journal Article
Open access
PDF file
IMIoannis-Fivos Megas
Ioannis-Fivos Megas
SDSarina Delavari
Sarina Delavari
AEAlejandro Marti Edo
Alejandro Marti Edo
GHGötz Habild
Götz Habild
MBMoritz Billner
Moritz Billner
David BreidungDavid Breidung
David Breidung
Introduction: Necrotizing fasciitis (NF) is a critical disease with high morbidity and mortality rates that poses significant challenges in diagnosis and treatment. Prognostic factors for the clinical course of NF remain unclear and are currently under research. This study aims to identify such factors in a large cohort of patients which represents a major comprehensive investigation of prognostic factors for NF. Methods: Retrospective analysis was conducted on necrotizing fasciitis cases from 2003 to 2023 at two German hospitals. Data included demographics, comorbidities, laboratory findings, infection site, causative microorganisms and outcomes. Statistical analysis involved t-tests, chi-square tests, and ROC analysis. Results: A total of 209 patients were included, with a mortality rate of 18%. Patients were categorized into survivors (n = 171) and non-survivors (n = 38). Non-survivors were significantly older (68.9 ± 13.9 years vs. 55.9 ± 14.3 years; p < 0.01) and exhibited a higher prevalence of peripheral vascular diseases, cancer, and heart, liver, or renal insufficiency. Laboratory findings and scoring results also varied significantly between the two groups. The ROC curve analysis identified age as a predictor of mortality, with an optimal cut-off value of 68.5 years (sensitivity: 60.5%, specificity: 81.9%). Higher age was associated with increased mortality risk. Conclusions: The patient’s age stands out as the primary predictive element for mortality in necrotizing fasciitis. Additionally, we advocate for employing the Laboratory and Anamnestic Risk Indicator for Necrotizing Fasciitis (LARINF—score), which holds substantial prognostic significance and is straightforward to calculate. Considering our findings, crafting a clinical algorithm or scoring mechanism to forecast mortality in NF would be a promising target for future research.